Concepedia

Emilie Scherrer

ES

3

Publications

40

Citations

3

H-Index

2020

Active since

Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)(Current)

Emilie Scherrer is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in cancer therapeutics, cancer research, and radiation oncology.

ORCID

Top concepts

Publications per year

2020–2022

3

Publications

3

An Economic Evaluation of Pembrolizumab Versus Other Adjuvant Treatment Strategies for Resected High-Risk Stage III Melanoma in the USA

Arielle G. Bensimon, Zheng‐Yi Zhou, Madeline Jenkins et al. · Clinical Drug Investigation · 2020 · 17 citations · Full text

Real-World Therapy with Pembrolizumab: Outcomes and Surrogate Endpoints for Predicting Survival in Advanced Melanoma Patients in Germany

Peter Mohr, Emilie Scherrer, Chalid Assaf et al. · Cancers · 2022 · 12 citations · Full text

, , +13

Outcomes of Retreatment with Anti-PD-1 Monotherapy after Response to First course in Patients with Cutaneous Melanoma

Eric D. Whitman, Emilie Scherrer, Wanmei Ou et al. · Future Oncology · 2020 · 11 citations · Full text

Rows per page

1–3 of 3